listened Comprehensive Notes on Non Self-Administered, Nonhormonal Contraception, and Pregnancy Termination

Digital Health and Contraceptive Mobile Applications

  • FDA Oversight of Mobile Medical Applications:     * The FDA maintains oversight of software functions that meet the definition of a medical device.     * The primary concern is functionality that could pose a risk to patient safety if it fails to function as intended.     * Policy was last updated in September 20222022.

  • Natural Cycles (Cycle App):     * FDA-approved for users 1818 years of age and older.     * Requires an annual subscription and the use of a basal body temperature thermometer.     * Efficacy Rates:         * Typical Use: 93%93\% effective.         * Perfect Use: 98%98\% effective.     * Data Entry: Users record basal body temperature every morning.     * Wearable Compatibility: NC Band, Oura Ring, Garmin Watch, and Apple Watch.     * Output: Provides a daily fertility status.

  • Clue Birth Control (Cycle App):     * Received FDA clearance in 20212021 but has not yet fully launched as of the lecture data (Clue cycle tracking app is available).     * Efficacy Rates:         * Typical Use: 92%92\% effective.         * Perfect Use: 97%97\% effective.     * Criteria for Use: Users aged 18−4518-45 with cycles between 20−4020-40 days in length, with a variance of 99 days or less.     * Mechanism: Uses documentation of "cycle day 11" and does not appear to require basal body temperature monitoring.

  • Other Available Tracking Apps:     * Ovia Health, Flo, MyFlo, MagicGirl (specifically designed for teens), Cycles, Eve by Glow, Glow, Apple Cycle Tracking, Spot On, and Period Tracker.

Lactic Acid, Citric Acid, and Potassium Bitartrate Vaginal Gel (Phexxi)

  • Overview:     * Approved for on-demand pregnancy prevention in females of reproductive potential.     * Product Content: Each single-dose (55 grams) pre-filled applicator contains:         * 90 mg90\,mg of lactic acid.         * 50 mg50\,mg of citric acid.         * 20 mg20\,mg of potassium bitartrate.     * Administration: Administer one 55-gram dose immediately before or up to 11 hour before each act of vaginal intercourse.     * Mechanism of Action: Lowers vaginal pH to reduce sperm motility.

  • Efficacy and Safety:     * Efficacy: Estimated Pearl Index (failures per 100100 women-years) is 27.527.5, which is approximately 73%73\% effective.     * Compatibility:         * Avoid use with vaginal rings.         * Safe for use with condoms, diaphragms, and vaginal infection treatments.     * Adverse Effects: Vaginal burning, itching, discomfort, hypersensitivity, and vaginal mycotic infections.     * Serious Reports: Instances of cystitis and pyelonephritis have been reported.

Depot Medroxyprogesterone Acetate (DMPA) - Contraceptive Injection

  • Product Formulations:     * Subcutaneous (SQ): 104 mg104\,mg administered every 33 months (12−1412-14 weeks).     * Intramuscular (IM): 150 mg150\,mg administered every 33 months (1313 weeks).     * CDC call in 20212021 recommended making self-administered SQ options available.

  • Adverse Effects:     * Menstrual Irregularities: Frequent breakthrough bleeding; 50−60%50-60\% of users become amenorrheic within 11 year.     * Weight Gain: Average of 5.4 lb5.4\,lb at 11 year and 16.5 lb16.5\,lb at 55 years.     * General: Headache (HAHA), bloating, breast tenderness, mood changes, and decreased libido.     * VTE Risk: Increased risk of Venous Thromboembolism (VTEVTE) compared to Progestin-only Pills (POPsPOPs).

  • Fertility Return: Delayed; median time to conception is 1010 months after the last injection (range of 4−314-31 months).

  • Bone Health Warning:     * Black Box Warning: Potential for decreased Bone Mineral Density (BMDBMD).     * Loss of 5−10%5-10\% BMDBMD over 55 years; loss increases with duration.     * May not be completely reversible.     * Recommendation: Not recommended for use longer than 22 years unless necessary; supplement with Calcium and Vitamin D.     * ACOG Position: Supports use >2>2 years and states BMDBMD measurements are not necessary, as BMDBMD mostly recovers (though recovery at the hip/femoral neck in adolescents is a concern).

  • Non-Contraceptive Benefits:     * Decreased risk of endometrial cancer.     * 30%30\% reduction in seizures for women with epilepsy.     * 70%70\% reduction in acute sickle cell crises (caution regarding possible VTEVTE risk).     * Improved iron-deficiency anemia due to reduced menstrual cycles.     * Effective regardless of weight or drug interactions.

  • Initiation Protocols:     * Start if "reasonably certain" not pregnant.     * Within 7 days of menses start: No backup needed.     * After 7 days of menses start (or amenorrhea): Use backup for 77 days.     * Postpartum: Can start any time. No backup if < 66 months, amenorrheic, and fully breastfeeding. Otherwise, backup for 77 days if > 2121 days postpartum.

  • Dosing Windows:     * Early: No limit.     * Late: Up to 22 weeks late (1515 weeks from last dose) requires no backup.     * Over 22 weeks late (>15>15 weeks): Requires backup for 77 days and possible emergency contraception (ECEC).

  • Bleeding Management:     * Rule out other causes first.     * Treatment: NSAIDsNSAIDs for 5−75-7 days during bleeding; low-dose COCsCOCs or estrogen for 10−2010-20 days for heavy bleeding.

Long-Acting Reversible Contraceptives (LARCs) - Intrauterine Devices (IUDs)

  • Levonorgestrel (LNG) IUDs:     * Skyla: 13.5 mg13.5\,mg LNG; lasts 33 years.     * Kyleena: 19.5 mg19.5\,mg LNG; lasts 55 years.     * Mirena: 52 mg52\,mg LNG; lasts 88 years.     * Liletta: 52 mg52\,mg LNG; lasts 88 years.

  • Copper IUDs (Nonhormonal):     * ParaGard: Copper T; lasts 1010 years.     * Miudella: Copper T; lasts 33 years.

  • Mechanisms of Action (MOA):     * Inhibits fertilization via thickened cervical mucus and inhibited sperm function.     * Endometrium suppression and weak foreign body reaction induction.     * Ovulation is generally not inhibited (most cycles are ovulatory), though Mirena may inhibit some.

  • Efficacy: Highly efficacious with failure rates <0.9%< 0.9\%.

  • Placement and Timing:     * Insert any time patient is reasonably certain not pregnant.     * Copper IUD: No backup needed.     * LNG IUD: Backup for first 77 days if inserted >7>7 days since menses began.     * STD Screening: Do not delay for screening unless infection is highly likely. If an STD occurs while the IUD is in place, treat the STD; IUD removal is only considered if symptoms don't resolve in 48−7248-72 hours (CDC MEC Category 22).

  • Adverse Effects:     * Mild bleeding/cramping (1−21-2 days); irregular breakthrough bleeding for 66 months.     * 20%20\% amenorrhea rate at 11 year.     * Expulsion risk: 3−5%3-5\% within days 1−121-12; 2%2\% after day 1212.

Long-Acting Reversible Contraceptives (LARCs) - Etonogestrel Implant

  • Nexplanon:     * 68 mg68\,mg Etonogestrel single rod (matchstick-sized).     * Implanted subdermally; effective for up to 55 years.     * Requires specific training for provider insertion and removal.

  • Initiation:     * Within 55 days of menses start: No backup.     * After 55 days (or amenorrhea): Backup for 77 days.     * Postpartum: Same rules as DMPA (fully breastfeeding/amenorrheic vs. 77-day backup).

  • Adverse Effects:     * Irregular Bleeding: Most common side effect; requires proactive counseling.     * General: Headaches, acne, emotional lability, weight increase, depression, site reactions.

  • Bleeding Management:     * Hormonal Treatment: Low-dose COCsCOCs or estrogen (10−2010-20 days).     * Antifibrinolytic: Tranexamic acid for 55 days.     * NSAIDsNSAIDs: 5−75-7 days during bleeding episodes.     * SERMsSERMs: Tamoxifen for 7−107-10 days.

Emergency Contraception (EC)

  • Levonorgestrel (LNG) - Plan B One-Step / Next Choice:     * Dose: 1.5 mg1.5\,mg tablet once.     * Timing: Use ASAP within 55 days (120 hours).     * Efficacy: 74%74\% if within 7272 hours; 63%63\% between days 4−54-5.     * Repeat Dosing: Repeat if vomited within 22 hours.     * Weight Consideration: May lose efficacy in women >165 lb> 165\,lb and lose it completely in women >175 lb> 175\,lb.

  • Ulipristal Acetate (UPA) - Ella:     * Dose: 30 mg30\,mg tablet once (RxRx only).     * Timing: Maintains high efficacy for the full 55 days.     * Repeat Dosing: Repeat if vomited within 33 hours.     * Warning: Could harm a fetus; do not use if pregnancy from a previous act is suspected.

  • Copper IUD (ParaGard):     * $> 99\%effective.    ∗Canbeinserteduptoeffective.     * Can be inserted up to5daysafterintercourse.</p></li><li><p><strong>LNGIUDforEC</strong>:    ∗Non−inferiortoCopperIUDforEC(Researchshowsdays after intercourse.</p></li><li><p><strong>LNG IUD for EC</strong>:     * Non-inferior to Copper IUD for EC (Research shows1pregnancyinpregnancy in317forLNGvs.for LNG vs.0inin321forCopper).</p></li><li><p><strong>MechanismsofEC</strong>:    ∗Inhibitsordelaysovulation(UPAdelaysforfor Copper).</p></li><li><p><strong>Mechanisms of EC</strong>:     * Inhibits or delays ovulation (UPA delays for5days).    ∗ImplantationinhibitionisprobablewithUPA,improbablewithLNG.</p></li><li><p><strong>DrugInteractions</strong>:    ∗Botharemajordays).     * Implantation inhibition is probable with UPA, improbable with LNG.</p></li><li><p><strong>Drug Interactions</strong>:     * Both are major3A4substrates.Stronginducers(e.g.,Carbamazepine,Phenytoin,Rifampin,St.Johnsˊwort)decreaseeffectiveness.    ∗UPAefficacydecreasedbymedicationsincreasinggastricpH(substrates. Strong inducers (e.g., Carbamazepine, Phenytoin, Rifampin, St. John\'s wort) decrease effectiveness.     * UPA efficacy decreased by medications increasing gastric pH (PPIs,,H_2blockers,antacids).</p></li><li><p><strong>ECFollow−UpandContraceptionInitiation</strong>:    ∗StartingregularBCafterLNG:Immediately.    ∗StartingregularBCafterUPA:Waitblockers, antacids).</p></li><li><p><strong>EC Follow-Up and Contraception Initiation</strong>:     * Starting regular BC after LNG: Immediately.     * Starting regular BC after UPA: Wait5daysbeforestartinghormonalmethods.    ∗Backuprequired:days before starting hormonal methods.     * Backup required:7daysorabstain.    ∗Pregnancytestifmensesisdays or abstain.     * Pregnancy test if menses is> 1weeklateornomensesinweek late or no menses in3weeks.</p></li></ul><h3id="b85b32f1−634f−4e16−bbcf−62ac3e8e0399"data−toc−id="b85b32f1−634f−4e16−bbcf−62ac3e8e0399"collapsed="false"seolevelmigrated="true">SpecialPatientPopulationsandContraception</h3><ul><li><p><strong>AgeandMenopause</strong>:    ∗Medianmenopauseageisweeks.</p></li></ul><h3 id="b85b32f1-634f-4e16-bbcf-62ac3e8e0399" data-toc-id="b85b32f1-634f-4e16-bbcf-62ac3e8e0399" collapsed="false" seolevelmigrated="true">Special Patient Populations and Contraception</h3><ul><li><p><strong>Age and Menopause</strong>:     * Median menopause age is51((40-60range).    ∗range).     *FSHtestsarenotaccuratedeterminantsofinfertility.    ∗Canusecontraceptivesuntilagetests are not accurate determinants of infertility.     * Can use contraceptives until age50-55.</p></li><li><p><strong>PerimenopausalConsiderations</strong>:    ∗LNGIUDshelpwithheavymensesandprotectagainstendometrialhyperplasia(off−label).    ∗.</p></li><li><p><strong>Perimenopausal Considerations</strong>:     * LNG IUDs help with heavy menses and protect against endometrial hyperplasia (off-label).     *COCsrelieveperimenopausalsymptomsbuthavehigherrelieve perimenopausal symptoms but have higherVTEriskviathepatch.</p></li><li><p><strong>OverweightandObeseWomen</strong>:    ∗NochangeinefficacyforDMPA,LNGIUD,orEtonogestrelimplant.    ∗risk via the patch.</p></li><li><p><strong>Overweight and Obese Women</strong>:     * No change in efficacy for DMPA, LNG IUD, or Etonogestrel implant.     *COCs:Limiteddatafor: Limited data forBMI > 35.MoststudiesshownosignificantdifferenceinefficacyforBMIupto. Most studies show no significant difference in efficacy for BMI up to35.</p></li><li><p><strong>TransgenderMen</strong>:    ∗Testosteroneusedoesnotpreventpregnancy;contraceptivecounselingisessentialforthosewithauterus.</p></li></ul><h3id="2b899871−af28−4edb−bba9−518973b38c96"data−toc−id="2b899871−af28−4edb−bba9−518973b38c96"collapsed="false"seolevelmigrated="true">PregnancyLossandElectiveTermination</h3><ul><li><p><strong>Definitions</strong>:    ∗<strong>SpontaneousAbortion</strong>:Miscarriage(non−preventable).Confirmedbyultrasound(emptysacornofetalheartactivity).    ∗<strong>RiskFactors</strong>:Increaseswithmaternalage(.</p></li><li><p><strong>Transgender Men</strong>:     * Testosterone use does not prevent pregnancy; contraceptive counseling is essential for those with a uterus.</p></li></ul><h3 id="2b899871-af28-4edb-bba9-518973b38c96" data-toc-id="2b899871-af28-4edb-bba9-518973b38c96" collapsed="false" seolevelmigrated="true">Pregnancy Loss and Elective Termination</h3><ul><li><p><strong>Definitions</strong>:     * <strong>Spontaneous Abortion</strong>: Miscarriage (non-preventable). Confirmed by ultrasound (empty sac or no fetal heart activity).     * <strong>Risk Factors</strong>: Increases with maternal age (17\%atageat age30;;80\%atageat age45).</p></li><li><p><strong>Misoprostol(ProstaglandinE1Analog)</strong>:    ∗<strong>MOA</strong>:Causescervicalsofteninganddilation.    ∗<strong>DosingforEarlyLoss</strong>:).</p></li><li><p><strong>Misoprostol (Prostaglandin E1 Analog)</strong>:     * <strong>MOA</strong>: Causes cervical softening and dilation.     * <strong>Dosing for Early Loss</strong>:800\,mcgvaginallyonce(repeatasneeded).    ∗<strong>OtherUses</strong>:GIulcerprevention,IUDinsertionpre−treatment(vaginally once (repeat as needed).     * <strong>Other Uses</strong>: GI ulcer prevention, IUD insertion pre-treatment (400\,mcg2-3hoursprior).</p></li><li><p><strong>Mifepristone(Mifeprex−ProgesteroneAntagonist)</strong>:    ∗Approvedforterminationthroughhours prior).</p></li><li><p><strong>Mifepristone (Mifeprex - Progesterone Antagonist)</strong>:     * Approved for termination through10weeks(weeks (70daysgestation).    ∗<strong>REMSProgram(Mod.1/3/23)</strong>:Requirescertifiedprescribersandpharmacies.Prescriber/Patientagreementformsrequired.    ∗<strong>Regimen</strong>:days gestation).     * <strong>REMS Program (Mod. 1/3/23)</strong>: Requires certified prescribers and pharmacies. Prescriber/Patient agreement forms required.     * <strong>Regimen</strong>:200\,mgMifepristonefollowedbyMifepristone followed by800\,mcgMisoprostolbuccallywithinMisoprostol buccally within24-48hours.</p></li><li><p><strong>SafetyandWarnings</strong>:    ∗Riskofseriousbacterialinfection/sepsisandprolongedheavybleeding.    ∗Expectedbleeding:hours.</p></li><li><p><strong>Safety and Warnings</strong>:     * Risk of serious bacterial infection/sepsis and prolonged heavy bleeding.     * Expected bleeding:9-16days(days (8\%experienceexperience> 30days).    ∗Contraindication:Ectopicpregnancy.    ∗SideEffects:Nausea(days).     * Contraindication: Ectopic pregnancy.     * Side Effects: Nausea (75\%$$), weakness, fever, vomiting, headache, diarrhea, and dizziness.